Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.04 SGD
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:31 AM 04/22/15 All times are local (Market data is delayed by at least 15 minutes).

pharmesis international ltd (PHM) Snapshot

Open
$0.04
Previous Close
$0.04
Day High
$0.04
Day Low
$0.04
52 Week High
06/9/14 - $0.05
52 Week Low
03/20/15 - $0.03
Market Cap
7.6M
Average Volume 10 Days
3.9K
EPS TTM
$-0.02
Shares Outstanding
200.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMESIS INTERNATIONAL LTD (PHM)

Related News

No related news articles were found.

pharmesis international ltd (PHM) Related Businessweek News

No Related Businessweek News Found

pharmesis international ltd (PHM) Details

Pharmesis International Ltd., an investment holding company, develops, manufactures, and sells western medicines, health tonic products, and traditional Chinese medicine (TCM) formulated products in the People’s Republic of China. The company operates through Western Drugs, TCM Formulated Drugs, and Distribution segments. It is also involved in the wholesale of chemical drugs, biological raw products, TCMs, antibiotics, and antibiotics agents. The company offers its western medicines and TCM formulated products in the form of tablets, granules, pills, etc. Its products comprise Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Xiao Shi Jian Pi tablets for flatus, inappetency, dyspepsy, and spleen weakness; and Lianpu Shuangqing for the treatment of acute inflammation, such as dysentery and intestinal infection. Pharmesis International Ltd. also offers Shulinghou tablets, which clear heat and regenerate body fluid, as well as for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Xiaoluotong Jiaonang for treating rheumatoid arthritis and other rheumatic diseases; and Afenka for the treatment of migrane, pain from headache, cold, nasosinusitis, muscle pain, menstrual pain, toothache, and arthritis. In addition, the company provides Er Ding granules for the treatment of jaundice and heat toxic clearance; Bear Bile and Bulbus Fritillariae oral liquid for the treatment of phlegm-heat cough; and Gansu for the treatment of acute and chronic hepatitis; and Gansu for the treatment of acute and chronic hepatitis. Pharmesis International Ltd. markets its western drugs under the Kinna brand name; and TCM formulated drugs under the Longlife brand name to approximately 2,000 hospitals through its sales and marketing personnel. The company was founded in 1996 and is headquartered in Chengdu, the People’s Republic of China.

Founded in 1996

pharmesis international ltd (PHM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $214.0K
Compensation as of Fiscal Year 2014.

pharmesis international ltd (PHM) Key Developments

Pharmesis International Ltd. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Pharmesis International Ltd. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss attributable to equity holders of the company of RMB 3,106,000 on revenue of RMB 15,130,000 compared to net profit attributable to equity holders of the company of RMB 1,763,000 on revenue of RMB 17,607,000 reported in the same period last year. Loss from operations was RMB 3,548,000 against profit from operations of RMB 1,962,000 reported last year. Loss before tax was RMB 2,898,000 against profit before tax of RMB 2,012,000 reported last year. Net cash flows from operating activities was RMB 4,589,000 against net cash used in operating activities of RMB 1,404,000 reported last year. Acquisition of property, plant and equipment was RMB 235,000 against RMB 145,000 reported last year. Decrease in revenue was mainly due to lower sales of key products (namely ATT and Gansu) and discontinued production of Huangke as management had decided to terminate production as it was no longer economically viable to produce because of escalated cost for a key raw material and inability to raise prices. For the year, the company reported net loss attributable to equity holders of the company of RMB 3,805,000 or 1.90 cents per diluted share on revenue of RMB 60,848,000 compared to net profit attributable to equity holders of the company of RMB 475,000 or 0.24 cents per diluted share on revenue of RMB 64,679,000 reported in the same period last year. Loss from operations was RMB 7,271,000 against profit from operations of RMB 858,000 reported last year. Loss before tax was RMB 4,602,000 against profit before tax of RMB 963,000 reported last year. Net cash flows from operating activities was RMB 8,696,000 against RMB 1,761,000 reported last year. Acquisition of property, plant and equipment was RMB 529,000 against RMB 596,000 reported last year.

Pharmesis International Ltd. to Report Fiscal Year 2014 Results on Feb 27, 2015

Pharmesis International Ltd. announced that they will report fiscal year 2014 results on Feb 27, 2015

Pharmesis International Ltd., Board Meeting, Nov 07, 2014

Pharmesis International Ltd., Board Meeting, Nov 07, 2014. Agenda: To consider unaudited financial results for the third quarter ended September 30, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHM:SP $0.04 SGD 0.00

PHM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PHM.
View Industry Companies
 

Industry Analysis

PHM

Industry Average

Valuation PHM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.6x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMESIS INTERNATIONAL LTD, please visit www.pharmesis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.